Following the launch of two new cancer tests—plus a third planned for before the end of 2025—Exact Sciences is nudging up its ...

the faster the cancer returned. “Our findings suggest that circulating tumor DNA tests could help oncologists identify which melanoma patients are most likely to respond well to therapy,” said ...

Researchers have developed a personalized blood test that may offer a faster, less invasive way to track high-grade glioma progression.

they can order the Signatera kit as well. Natera then uses that personalized test to look for evidence of that cancer's circulating tumor DNA. Natera can pick up evidence of a tumor sometimes ...

Monitoring blood levels of DNA fragments ... than other experimental tests that examine a tumor itself, such as those that measure immune activity within a group of cancer cells.

the faster cancer returned. "Our findings suggest that circulating tumor DNA tests could help oncologists identify which melanoma patients are most likely to respond well to therapy," said study ...

The pre-analytical workflow is one of the primary considerations in the successful use of liquid biopsies for cancer ...

A new, error-corrected method for detecting cancer from blood samples ... low concentrations of circulating tumor DNA. Adding an error-correcting method greatly improved the accuracy of the technique.

The new test looks for a specific type of DNA shed by tumors of stage III melanoma patients who, if found, indicates a strong likelihood their cancer will return in the aftermath of lymph node ...

Up to 90% of colorectal cancers can be cured if caught early. Learn about screening options at Fred Hutch to protect your health.

SPOT-MAS, a revolutionary blood test, provides the potential for early cancer detection by identifying circulating tumor DNA in the bloodstream, often before any symptoms manifest. This technology ...